Meeting
2014 ASCO Annual Meeting
Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).
Authors
Scott N. Gettinger
Yale University, New Haven, CT
Scott N. Gettinger , Lyudmila Bazhenova , Ravi Salgia , Corey J. Langer , Kathryn A. Gold , Rafael Rosell , Alice Tsang Shaw , Glen J. Weiss , Narayana I. Narasimhan , David J. Dorer , Victor M. Rivera , Tim Clackson , Frank G. Haluska , D. Ross Camidge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01449461
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8047)
DOI
10.1200/jco.2014.32.15_suppl.8047
Abstract #
8047
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
First Author: Edward S. Kim
Poster
2018 ASCO Annual Meeting
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
First Author: Benjamin Besse
Poster
2015 ASCO Annual Meeting
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).
First Author: D. Ross Camidge
Poster
2024 ASCO Annual Meeting
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
First Author: Kyle Concannon